|
1.
|
|
7 p, 1.3 MB |
Use of an acellular collagen-elastin matrix to support bladder regeneration in a porcine model of peritoneocystoplasty
/
Gasanz, Carlos (Hospital Universitari Vall d'Hebron) ;
Raventós, Carles (Universitat Autònoma de Barcelona. Departament de Cirurgia) ;
Temprana-Salvador, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Esteves, Marielle (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Fonseca, Carla (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de Torres, Inés (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Morote Robles, Juan (Universitat Autònoma de Barcelona. Departament de Cirurgia)
Bladder reconstruction without using the intestine remains a challenge to this day despite the development of new biomaterials and cell cultures. Human bladder engineering is merely anecdotic, and mostly in vitro and animal studies have been conducted. [...]
2018 -  10.5173/ceju.2018.1735
Central European Journal of Urology, Vol. 71 (august 2018) , p. 353-359
|
|
|
2.
|
|
16 p, 4.3 MB |
Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival
/
Vilardell, Jordi (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ;
Alcaraz Muñoz, Estefania (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ;
Sarró, Eduard (Vall d'Hebron Institut de Recerca) ;
Trilla, Enric (Hospital Vall d'Hebrón) ;
Cuadros, Thaïs (FVall d'Hebron Institut de Recerca) ;
Torres Ramírez, Inés Ma. de (Hospital Vall d'Hebrón) ;
Plana, Maria (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ;
Ramón y Cajal, Santiago (Hospital Vall d'Hebrón) ;
Pinna, Lorenzo A. (University of Padova) ;
Ruzzene, Maria (University of Padova) ;
Morote Robles, Juan (Hospital Uniersitari Vall d'Hebrón) ;
Meseguer, Anna (Universitat Autònoma de Barcelona. Departament de Bioquimica i Biologia Molecular) ;
Itarte, Emilio (Universitat Autònoma de Barcelona. Departament de Bioquimica i Biologia Molecular)
Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of renal cancer. STAT3 pathway is altered in these tumors and p-STAT3 Ser727 is an independent prognostic factor for ccRCC. [...]
2018 - 10.18632/oncotarget.23422
Oncotarget, Vol. 9, Num. 5 (January 2018) , p. 5736-5751
|
|
|
3.
|
|
11 p, 3.4 MB |
Low-dose statin treatment increases prostate cancer aggressiveness
/
Caro-Maldonado, Alfredo (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ;
Camacho, Laura (Biochemistry and Molecular Biology Department, University of the Basque Country, Bilbao, Spain) ;
Zabala-Letona, Amaia (CIBERONC, Madrid, Spain) ;
Torrano, Verónica (CIBERONC, Madrid, Spain) ;
Fernández-Ruiz, Sonia (CIBERONC, Madrid, Spain) ;
Zamacola-Bascaran, Kepa (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ;
Arreal, Leire (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ;
Valcárcel-Jiménez, Lorea (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ;
Martín-Martín, Natalia (CIBERONC, Madrid, Spain) ;
Flores, Juana M. (Department of Animal Medicine and Surgery, School of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain) ;
Cortazar, Ana R. (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ;
Zúñiga-García, Patricia (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ;
Arruabarrena-Aristorena, Amaia (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ;
Guillaumond, Fabienne (Université Aix-Marseille, Marseille, France) ;
Cabrera, Diana (CIC bioGUNE, Bizkaia Technology Park, Derio, Spain) ;
Falcón-Perez, Juan M. (IKERBASQUE, Basque foundation for science, Bilbao, Spain) ;
Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain) ;
Gomez-Muñoz, Antonio (Biochemistry and Molecular Biology Department, University of the Basque Country, Bilbao, Spain) ;
Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Carracedo, Arkaitz (IKERBASQUE, Basque foundation for science, Bilbao, Spain) ;
Universitat Autònoma de Barcelona
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. [...]
2017 - 10.18632/oncotarget.22217
Oncotarget, Vol. 9 (october 2017) , p. 1494-1504
|
|
|
4.
|
|
|
5.
|
|
16 p, 5.8 MB |
Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
/
Cánovas, Verónica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Puñal, Yolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Maggio, Valentina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Redondo, Enric (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Marín, Mercedes (Laboratory of Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncoloy Department, Hospital Clinic, Barcelona, Spain) ;
Mellado, Begoña (Laboratory of Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncoloy Department, Hospital Clinic, Barcelona, Spain) ;
Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lleonart, Matilde (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Planas, Jacques (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Paciucci, Rosanna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Metastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, first described in prostate cancer, was reported as overexpressed and significantly correlated with poor survival in numerous tumors. [...]
2017 - 10.18632/oncotarget.19467
Oncotarget, Vol. 8 (july 2017) , p. 59165-59180
|
|
|
6.
|
|
|
7.
|
|
17 p, 5.0 MB |
Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer
/
Sequeiros, Tamara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rigau, Marina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Chiva, Cristina (Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain) ;
Montes, Melania (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Garcia-Grau, Iolanda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Garcia, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Diaz, Sherley (Hospital Universitari Vall d'Hebron) ;
Celma, Ana (Hospital Universitari Vall d'Hebron) ;
Bijnsdorp, Irene (Department of Urology, VU University Medical Center, Amsterdam, The Netherlands) ;
Campos, Alex (Sanford-Burnham Medical Research Institute, La Jolla, California, USA) ;
Di Mauro, Primiano (Sagetis-Biotech; Grup d'Enginyeria de Materials (GEMAT) Institut Químic de Sarrià, Barcelona, Spain) ;
Borrós, Salvador (Sagetis-Biotech; Grup d'Enginyeria de Materials (GEMAT) Institut Químic de Sarrià, Barcelona, Spain) ;
Reventós, Jaume (IDIBELL-Bellvitge Biomedical Research Institute, Barcelona, Spain) ;
Doll, Andreas (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Paciucci, Rosanna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Pegtel, Michiel (Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands) ;
de Torres, Inés (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sabidó, Eduard (Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain) ;
Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. [...]
2016 - 10.18632/oncotarget.13634
Oncotarget, Vol. 8 (november 2016) , p. 4960-4976
|
|
|
8.
|
|
11 p, 2.3 MB |
Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines
/
Olivan, M. (Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain) ;
Rigau, M. (RHospital Universitari Vall d'Hebron. Institut de Recerca) ;
Colás, E. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Garcia, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Montes, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sequeiros, T. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Regis, L. (Hospital Universitari Vall d'Hebron) ;
Celma, A. (Hospital Universitari Vall d'Hebron) ;
Planas, J. (Hospital Universitari Vall d'Hebron) ;
Placer, J. (Hospital Universitari Vall d'Hebron) ;
Reventós, J. (Hospital Universitari de Bellvitge. Institut d'Investigació Biomèdica de Bellvitge) ;
de Torres, I. (Hospital Universitari Vall d'Hebron) ;
Doll, A. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Morote Robles, Juan. (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Nowadays prostate cancer is the most common solid tumor in men from industrialized countries and the second leading cause of death. At the ages when PCa is usually diagnosed, mortality related to cardiovascular morbidity is high; therefore, men at risk for PCa frequently receive chronic lipid-lowering and antiplatelet treatment. [...]
2015 - 10.1155/2015/762178
BioMed Research International, Vol. 2015 (january 2015)
|
|
|
9.
|
|
9 p, 695.8 KB |
Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness
/
Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Celma, Anna (Hospital de la Vall Hebron. Departament d'Urologia) ;
Planas, Jacques (Hospital de la Vall Hebron. Departament d'Urologia) ;
Placer, José (Hospital de la Vall Hebron. Departament d'Urologia) ;
de Torres, Inés (Hospital de la Vall Hebron. Departament de Patologia) ;
Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Carles, Juan (Universitat Internacional de Catalunya. Department de Ciències Bàsiques) ;
Reventós, Jaume (IDIBELL-Institut d'Investigació Biomèdica de Bellvitge) ;
Doll, Andreas (DUniversitat Internacional de Catalunya. Department de Ciències Bàsiques)
The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. [...]
2014 - 10.3390/ijms150813615
International journal of molecular sciences, Vol. 15 (august 2014) , p. 13615-13623
|
|
|
10.
|
|
30 p, 2.0 MB |
The Present and Future of Prostate Cancer Urine Biomarkers
/
Rigau, Marina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Olivan, Mireia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Garcia, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sequeiros, Tamara (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Montes, Melania (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Colás, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Llauradó, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Planas, Jacques (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de Torres, Inés (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Morote Robles, Juan (Universitat Autònoma de Barcelona. Departament de Cirurgia) ;
Cooper, Colin (Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK; E-Mails: (C.C.); (J.C.)) ;
Reventós, Jaume (Department of Basic Sciences, International University of Catalonia, 08017 Barcelona, Spain) ;
Clark, Jeremy (Cancer Genetics, University of East Anglia, Norwich Norfolk, NR4 7TJ, UK; E-Mails: (C.C.); (J.C.)) ;
Doll, Andreas (Hospital Universitari Vall d'Hebron. Institut de Recerca)
In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. [...]
2013 - 10.3390/ijms140612620
International journal of molecular sciences, Vol. 14 (june 2013) , p. 12620-12649
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
